Evidence map›Paper›PMID 38064245›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.

Mia C Weiss, Vanessa Eulo, Brian A Van Tine

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Mia C WeissWashington University in St. Louis, School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, Missouri.ORCID 0000-0002-8457-0523
Vanessa EuloDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0003-2304-2222
Brian A Van TineWashington University in St. Louis, School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, Missouri.ORCID 0000-0003-4572-6668
Midwest Therapeutic Endoscopy · USSt. Louis Children's Hospital · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient's response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS. See related article by Gleason et al., p. 703.

Indexed as

LiposarcomaCyclin-Dependent Kinase 4Gene AmplificationHumansProto-Oncogene Proteins c-mdm2Cyclin-Dependent Kinase 4Proto-Oncogene Proteins c-mdm2

Identifiers

PMID38064245
OpenAlexW4389490178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.